SAN
DIEGO, May 22, 2023 /PRNewswire/ -- Poseida
Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene
therapy company advancing a new class of treatments for patients
with cancer and rare diseases, today announced that two
abstracts have been accepted for presentation at the
31st Congress of the International Society on Thrombosis
and Haemostasis (ISTH), being held in Montreal, Canada and virtually on June 24-28, 2023.
Details for the presentations are as follows:
Oral Presentation:
Title: Expression and Activity of Human Factor VIII
(hFVIII) Following Single and Repeat Administration of an
Integrating Non-viral Gene Therapy in Multiple Mouse Models of
Severe Hemophilia A
Presenter: Denise Sabatino, Ph.D., Research Associate
Professor of Pediatrics at the Perelman School of Medicine at the
University of Pennsylvania and
Children's Hospital of Philadelphia (CHOP)
Session Title: Hemophilia Gene Therapy Basic Science
Presentation Date/ Time: Monday, June
26, 2023, at 11:45 AM - 12:00 PM
ET
Abstract Presentation Number: OC 30.6
Location: Room 517
Poster Presentation:
Title: Development of a Non-viral Gene Therapy
Approach for Severe Bleeding Disorders
Presenter:
Brian Truong, Ph.D., Senior
Scientist at Poseida Therapeutics
Session Title: Poster Networking
Session
Session Date/ Time: Sunday, June 25,
2023, at 6:30 PM - 7:30 PM ET
Abstract Presentation Number: PB0182
Location: Exhibition Hall
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical
company advancing differentiated cell and gene therapies with the
capacity to cure certain cancers and rare diseases. The Company's
pipeline includes allogeneic CAR-T cell therapy product candidates
for both solid and liquid tumors as well as in vivo gene therapy
product candidates that address patient populations with high unmet
medical need. The Company's approach to cell and gene therapies is
based on its proprietary genetic editing platforms, including its
non-viral piggyBac® DNA Delivery System,
Cas-CLOVER™ Site-Specific Gene Editing System and
nanoparticle and hybrid gene delivery technologies. The Company has
formed global strategic collaborations with Roche and Takeda to
unlock the promise of cell and gene therapies for patients. Learn
more at www.poseida.com and connect with Poseida on Twitter and
LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include statements
regarding, among other things, expected plans with respect to
clinical trials, including timing of regulatory submissions and
approvals and clinical data updates; potential fees, milestones and
other payments that the Company may receive pursuant to its
collaboration agreements; anticipated timelines and milestones with
respect to the Company's development programs and manufacturing
activities and capabilities; the potential capabilities and
benefits of the Company's technology platforms and product
candidates; and the Company's plans and strategy with respect to
developing its technologies and product candidates. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. These forward-looking statements are
based upon the Company's current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
the Company's reliance on third parties for various aspects of its
business; risks and uncertainties associated with development and
regulatory approval of novel product candidates in the
biopharmaceutical industry; the Company's ability to retain key
scientific or management personnel; the fact that the Company will
have limited control over the efforts and resources that its
strategic partners devote to advancing development programs under
their respective collaboration agreements and the Company may not
receive the potential fees and payments under the collaboration
agreements and the ability of its strategic partners to early
terminate the collaborations, such that the Company may not fully
realize the benefits of such collaborations; and the other risks
described in the Company's filings with the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. The
Company undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-31st-congress-of-the-international-society-on-thrombosis-and-haemostasis-301829942.html
SOURCE Poseida Therapeutics, Inc.